115 related articles for article (PubMed ID: 27798858)
1. Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma.
Hayashi T; Kawano M; Ichimura T; Ida K; Ando H; Zharhary D; Kanai Y; Aburatani H; Tonegawa S; Shiozawa T; Yaegashi N; Konishi I
Anticancer Res; 2016 Oct; 36(10):4997-5007. PubMed ID: 27798858
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcoma: present management.
Giuntoli RL; Bristow RE
Curr Opin Oncol; 2004 Jul; 16(4):324-7. PubMed ID: 15187886
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms of uterine leiomyosarcomas: involvement of defect in LMP2 expression.
Hayashi T; Shimamura Y; Saegusa T; Horiuchi A; Kobayashi Y; Hiraoka N; Kanai Y; Aburatani H; Sano K; Konishi I
Gene Regul Syst Bio; 2008 Jul; 2():297-305. PubMed ID: 19787091
[TBL] [Abstract][Full Text] [Related]
4. Potential diagnostic biomarkers: differential expression of LMP2/β1i and cyclin B1 in human uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Ichimura T; Sudo T; Ishiko O; Yaegashi N; Aburatani H; Konishi I
Tumori; 2014; 100(4):99e-106e. PubMed ID: 25296613
[TBL] [Abstract][Full Text] [Related]
5. Uterine Leiomyosarcoma Tumorigenesis in Lmp2-deficient Mice: Involvement of Impaired Anti-oncogenic Factor IRF1.
Hayashi T; Horiuchi A; Sano K; Yaegashi N; Konishi I
Anticancer Res; 2015 Sep; 35(9):4665-79. PubMed ID: 26254356
[TBL] [Abstract][Full Text] [Related]
6. Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kanai Y; Shiozawa T; Tonegawa S; Konishi I
Protein Cell; 2010 Aug; 1(8):711-7. PubMed ID: 21203912
[TBL] [Abstract][Full Text] [Related]
7. Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Tagawa Y; Nishimura R; Ishiko O; Kanai Y; Yaegashi N; Aburatani H; Shiozawa T; Konishi I
Sci Rep; 2011; 1():180. PubMed ID: 22355695
[TBL] [Abstract][Full Text] [Related]
8. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
Cui RR; Wright JD; Hou JY
BJOG; 2017 Jun; 124(7):1028-1037. PubMed ID: 28128524
[TBL] [Abstract][Full Text] [Related]
9. A novel diagnostic biomarker for human uterine leiomyosarcoma: PSMB9/β1i.
Hayashi T; Kawano M; Sano K; Ichimura T; Gur G; Yaish P; Zharhary D; Kanai Y; Tonegawa S; Shiozawa T; Yaegashi N; Konishi I
Chin Clin Oncol; 2017 Apr; 6(2):22. PubMed ID: 28482675
[No Abstract] [Full Text] [Related]
10. Potential role of LMP2 as an anti-oncogenic factor in human uterine leiomyosarcoma: morphological significance of calponin h1.
Hayashi T; Horiuchi A; Sano K; Hiraoka N; Kasai M; Ichimura T; Sudo T; Nishimura R; Ishiko O; Shiozawa T; Kanai Y; Yaegashi N; Aburatani H; Konishi I
FEBS Lett; 2012 Jun; 586(13):1824-31. PubMed ID: 22659265
[TBL] [Abstract][Full Text] [Related]
11. Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures.
Ravid Y; Formanski M; Smith Y; Reich R; Davidson B
Gynecol Oncol; 2016 Mar; 140(3):512-7. PubMed ID: 26768834
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
13. [Uterine leiomyosarcoma: epidemiology, pathology, biology, diagnosis, prognosis and treatment].
Hadoux J; Morice P; Lhommé C; Duvillard P; Balleyguier C; Haie-Meder C; Gouy S; Uzan C; Mazeron R; Tazi Y; Leary A; Duffaud F; Pautier P
Bull Cancer; 2013 Sep; 100(9):903-15. PubMed ID: 24004576
[TBL] [Abstract][Full Text] [Related]
14. Optimal management of uterine leiomyosarcoma.
O'Cearbhaill R; Hensley ML
Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
[TBL] [Abstract][Full Text] [Related]
15. "Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.
Veras E; Zivanovic O; Jacks L; Chiappetta D; Hensley M; Soslow R
Am J Surg Pathol; 2011 Nov; 35(11):1626-37. PubMed ID: 21921786
[TBL] [Abstract][Full Text] [Related]
16. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?].
Leung F; Terzibachian JJ; Gay C; Chung Fat B; Aouar Z; Lassabe C; Maillet R; Riethmuller D
Gynecol Obstet Fertil; 2009 Feb; 37(2):109-14. PubMed ID: 19200764
[TBL] [Abstract][Full Text] [Related]
17. Ovarian and uterine leiomyosarcoma: which one is the primary?
Shafiee MN; Kah Teik C; Md Zain RR; Kampan N
Horm Mol Biol Clin Investig; 2019 Aug; 41(2):. PubMed ID: 31398145
[TBL] [Abstract][Full Text] [Related]
18. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
Rao UN; Finkelstein SD; Jones MW
Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
[TBL] [Abstract][Full Text] [Related]
19. Primary and secondary leiomyosarcoma of the oral and perioral region--clinicopathological and immunohistochemical analysis of a rare entity with a review of the literature.
Schütz A; Smeets R; Driemel O; Hakim SG; Kosmehl H; Hanken H; Kolk A
J Oral Maxillofac Surg; 2013 Jun; 71(6):1132-42. PubMed ID: 23434173
[TBL] [Abstract][Full Text] [Related]
20. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
